Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Roche dominates 2019’s big patent expiries
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
Boston and Edwards make a smart judgement
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Medtech news over the Christmas period
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The most disputed sales outlooks in biopharma
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
No margin left for error at Acorda
Generic versions of Acorda’s Ampyra are about to flood the market, meaning that the company desperately needs a timely approval in October for its next big hope.
Biosimilars the beneficiary of new Medicare step therapy rule
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
More change needed to make US pricing truce permanent
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.